ArticleJournal of medical biochemistry2025
Serum biomarkers in oral lichen planus: A biochemical perspective.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Catestatin Level as a Novel Biomarker of Oral Lichen Planus.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal tissues of the oral cavity. Its pathogenesis involves immune dysregulation, angiogenesis, and psychological stress. Identifying reliable biomarkers can enhance diagnosis, monitor disease progression, and guide personalised treatment strategies. This study aimed to investigate five key serum biomarkers in OLP patients, including angiopoietin-2 (Ang-2), vitamin D, IgA, IgG, and cortisol, to explore their associations with disease severity. Methods: This observational, case-control study enrolled 100 OLP patients and 80 healthy controls. The OLP patients were classified into three subtypes: reticular (n=30), atrophic (n=35), and erosive (n=35). Fasting blood samples were collected, and serum levels of Ang-2, vitamin D, IgA, IgG, and cortisol were measured using ELISA, HPLC, immunoturbidimetry, and chemiluminescent immunoassays. Statistical analyses, including t-tests, ANOVA, and Pearson correlation, were performed to assess biomarker levels and their correlations with disease severity. Results: Ang-2, IgA, and IgG levels were significantly elevated in OLP patients, particularly in the erosive subtype (P<0.001), with positive correlations between these markers and disease severity. Vitamin D and cortisol levels were significantly reduced in OLP patients compared to controls (P<0.01) and showed negative correlations with disease severity. These findings indicate the role of vascular, immune, metabolic, and stress-related factors in OLP pathogenesis. Conclusions: Ang-2, vitamin D, IgA, IgG, and cortisol are valuable biomarkers for assessing OLP severity and guiding personalised treatment. Monitoring these biomarkers can aid in diagnosing OLP, tracking disease progression, and optimising therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.